This report was first published by Endpoints News. To see the original version, click here
Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line.
But the biotech’s stock $UPB dropped by 45% at market open Wednesday.
您已阅读13%（350字），剩余87%（2406字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。